Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.
Also called NCT01610141
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 500 participants
- Sponsor
- Registry
-
NCT01610141
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01610141. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients
- Condition
- Atrial Fibrillation
- Condition
- Deep Vein Thrombosis
- Condition
- Pulmonary Embolism
- Condition
- Heart Valve Disease
- Intervention (Other)
- Genotype-guided warfarin dosing
- Intervention (Other)
- Non-genotype guided warfarin dosing
- Lead sponsor
- Chinese PLA General Hospital
Record details
- Record id
cardio:ct-nct01610141- Content hash
2a212f6a87ae35f977192343c2b17924838ddaa3e0122619818fc0c817b18431